Disclosures and Acknowledgments All authors took part in the research, were actively involved in preparing the abstract, and have approved the final poster. CE, JO, and DL are employees and own stock options in Envision Pharma Group, a healthcare communications company that is funded by pharmaceutical companies to facilitate the creation of plain language summaries. DL serves on the ISMPP European Meeting Committee. LM is an employee of Envision Pharma Group. JW is a co-owner of Becaris Publishing and was a consultant for Future Science Group at the time this research was carried out. RJ is an employee of Future Science Group. Editorial and graphical support were provided by Helen Donaghy and James Julia of Envision Pharma Group. References 1. https://www.plainlanguagesummaries.com/. Accessed March 10, 2023. 2. Lobban D, Gardner J, Matheis R. Curr Med Res Opin. 2022;38:189-200. 3. International Committee of Medical Journal Editors. Recommendations: overlapping publications. https://www.icmje.org/recommendations/browse/publishing-and-editorial- issues/overlapping-publications.html. Accessed March 22, 2023. 4. DeTora LM, Toroser D, Sykes A, et al. Ann Intern Med. 2022;175:1298-1304. Presented at the 19th Annual Meeting of the International Society for Medical Publication Professionals (April 24-26, 2023; Washington DC, USA) Who Are the Authors of Plain Language Summaries of Publications? Catherine Elliotta, Jacqui Olivera, Lauren Manninga,b, Rachel Jenkinsc, Joanne Walkerd, Dawn Lobbana aEnvision Pharma Group, Wilmslow, UK bUniversity of Manchester, Manchester, UK cFuture Science Group, London, UK dBecaris Publishing, Royston, UK • Plain language summaries of publications (PLSPs) are peer-reviewed, standalone articles written in nontechnical language that present information from 1 or more publications. They are intended to be read and understood by nonspecialists1 • Ideally, PLSPs should include at least 1 author of the original publication to ensure accurate representation of the content1-4 • Our objective was to understand the authorship of PLSPs. We also wanted to explore if PLSPs with additional authors had further content such as individual perspective sections • We compared the authorship groups of PLSPs published in Future Science Group journals between August 5, 2020 and February 28, 2023, with those of the corresponding original publications • Our aims were to understand: • We also looked at the Altmetric scores and downloads of PLSPs with additional authors/perspective sections and how these compared with PLSPs without additional authors/perspective sections POSTER #58 Background and Objectives Research Design and Methods Results Conclusions Which therapy areas have PLSPs? Do PLSPs include additional authors and, if so, who are they? Do PLSPs include authors from the original publication? Do PLSPs with additional authors include added perspective sections not in the original publication? • Between August 5, 2020 and February 28, 2023, Future Science Group has published 72 PLSPs spanning a wide range of therapy areas ശThe majority of PLSPs focus on cancer (n=27), brain and nerves (n=14), rare diseases (n=11), and infections (n=11) • About a quarter of PLSPs (17/72) included additional authors compared with the original publications—the majority were patients or caregivers • Other additional authors included patient advocacy group representatives, nurse practitioners, science communicators, pharmaceutical industry employees, physicians, and clinical research staff • Almost all of the PLSPs (71/72) included at least 1 author from the original publication(s) • Most of the PLSPs (66/72) included a lead author from the original publication • Six of the 17 PLSPs with additional authors included a patient or caregiver perspective section ശTwo of these PLSPs also included other additional perspectives; one included a nursing perspective section, and the other a patient advocate perspective section Including a patient or caregi